Key result
TiAra aortic bioprosthesis yields stable hemodynamics with ~6% all-cause mortality over 28 months.
Why the study?
The effectiveness and safety of the new semi-rigid xenopericardial bioprosthesis TiAra in the long-term period after aortic valve replacement were not well studied.
Cohort (n=48)
No
Early safety data support evaluation of the TiAra bioprosthesis; leaves open its comparative role versus established valves.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Evtushenko et al. (2023) conducted a cohort in Degenerative aortic valve stenosis (n=48). TiAra xenopericardial semi-frame bioprosthesis was evaluated on Long-term all-cause mortality. The TiAra xenopericardial semi-frame bioprosthesis demonstrated stable hemodynamics with 0% valve-related mortality and a 6.3% all-cause mortality rate over a mean 28-month follow-up in patients with degenerative aortic valve stenosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: